Home  /  Resource Library  /  Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged >80 years with diffuse large B-cell lymphoma: a retrospective analysis

Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged >80 years with diffuse large B-cell lymphoma: a retrospective analysis

Real world study examined polatuzumab for treatment of elderly patients with DLBCL.